CD8A and neoplasm: Focusing on the changes observed in the immune compartment after virotherapy was administered to aPD-1 refractory tumors, the main readout seems to be that the treatment increased frequencies of multiple CD8 T-cell subpopulations in the tumor, covering different developmental and functional stages.